Table 4.

Influence of accelerated bone resorption on outcome in the absence of bisphosphonates

NTX ≥ 100 vs NTX <100Relative risk (95% confidence interval)P
Hormone refractory prostate cancer (n = 200)
    All SREs2.36 (1.30-4.29)0.021
    Time to first SRE2.56 (1.44-4.55)0.001
    Progressive disease2.17 (1.17-4.05)0.014
    Death5.09 (2.90-8.91)<0.001
Lung cancer and other solid tumors (n = 238)
    All SREs3.25 (2.26-4.68)<0.001
    Time to first SRE3.05 (1.95-4.72)<0.001
    Progressive disease2.02 (1.48-2.74)<0.001
    Death4.59 (2.82-7.46)<0.001
  • NOTE: Data adapted from ref. 31 and presented as a table.

    Abbreviation: SRE, skeletal-related event.